ARTICLE | Clinical News
Taligen Therapeutics preclinical data
October 6, 2008 7:00 AM UTC
TT32 reduced airway hyperresponsiveness (AHR) and eosinophilic airway inflammation in mice challenged with ovalbumin. The compound also attenuated goblet cell hyperplasia and TH2 cytokine production. ...